{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T13:13:43Z","timestamp":1788614023739,"version":"build-2803163510"},"reference-count":137,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100017950","name":"Shanghai Municipal Health Commission","doi-asserted-by":"publisher","award":["20224Y0307"],"award-info":[{"award-number":["20224Y0307"]}],"id":[{"id":"10.13039\/100017950","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81827807"],"award-info":[{"award-number":["81827807"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972218"],"award-info":[{"award-number":["81972218"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82273382"],"award-info":[{"award-number":["82273382"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972257"],"award-info":[{"award-number":["81972257"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272929"],"award-info":[{"award-number":["82272929"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82173116"],"award-info":[{"award-number":["82173116"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012247","name":"Program of Shanghai Academic Research Leader","doi-asserted-by":"publisher","award":["23XD1400600"],"award-info":[{"award-number":["23XD1400600"]}],"id":[{"id":"10.13039\/501100012247","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018531","name":"Major Science and Technology Projects in Yunnan Province","doi-asserted-by":"publisher","award":["202305AF150148"],"award-info":[{"award-number":["202305AF150148"]}],"id":[{"id":"10.13039\/501100018531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008750","name":"Shanghai Shenkang Hospital Development Center","doi-asserted-by":"publisher","award":["SHDC2020CR2017B"],"award-info":[{"award-number":["SHDC2020CR2017B"]}],"id":[{"id":"10.13039\/501100008750","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.seminoncol.2026.152505","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T15:50:44Z","timestamp":1779897044000},"page":"152505","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms"],"prefix":"10.1016","volume":"53","author":[{"given":"Han-Yu","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mao-Zhen","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin-hui","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Ang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4696-8098","authenticated-orcid":false,"given":"Wen-Quan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.seminoncol.2026.152505_bib0001","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.3748\/wjg.v28.i10.1009","article-title":"An update on the diagnosis of gastroenteropancreatic neuroendocrine neoplasms","volume":"28","author":"Fang","year":"2022","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152505_bib0002","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1007\/s13244-018-0658-6","article-title":"Imaging presentation of pancreatic neuroendocrine neoplasms","volume":"9","author":"Ciaravino","year":"2018","journal-title":"Insights Imaging"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152505_bib0003","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00261-020-02773-3","article-title":"Radiology of the neuroendocrine neoplasms of the gastrointestinal tract: a comprehensive review","volume":"46","author":"Malla","year":"2021","journal-title":"Abdom Radiol (NY)"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152505_bib0004","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1152\/physrev.00038.2010","article-title":"Normalization of the vasculature for treatment of cancer and other diseases","volume":"91","author":"Goel","year":"2011","journal-title":"Physiol Rev"},{"issue":"21","key":"10.1016\/j.seminoncol.2026.152505_bib0005","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0006","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.957068","article-title":"Angiogenesis in NENs, with a focus on gastroenteropancreatic NENs: from biology to current and future therapeutic implications","volume":"12","author":"Lauricella","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0007","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1007\/s12020-021-02942-4","article-title":"Angiogenic factors as prognostic markers in neuroendocrine neoplasms","volume":"76","author":"Puliani","year":"2022","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152505_bib0008","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.cell.2011.08.039","article-title":"Basic and therapeutic aspects of angiogenesis","volume":"146","author":"Potente","year":"2011","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152505_bib0009","doi-asserted-by":"crossref","first-page":"R519","DOI":"10.1530\/ERC-18-0025","article-title":"Role of the tumor microenvironment in digestive neuroendocrine tumors","volume":"25","author":"Cuny","year":"2018","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0010","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s11481-014-9531-7","article-title":"Vascular endothelial growth factor signaling in hypoxia and inflammation","volume":"9","author":"Ramakrishnan","year":"2014","journal-title":"J Neuroimmune Pharmacol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0011","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/s42003-024-05798-2","article-title":"NRP1 interacts with endoglin and VEGFR2 to modulate VEGF signaling and endothelial cell sprouting","volume":"7","author":"Sharma","year":"2024","journal-title":"Commun Biol"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0012","doi-asserted-by":"crossref","first-page":"241","DOI":"10.4161\/org.4.4.7414","article-title":"VEGF and endothelial guidance in angiogenic sprouting","volume":"4","author":"Gerhardt","year":"2008","journal-title":"Organogenesis"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0013","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a006569","article-title":"VEGF and notch in tip and stalk cell selection","volume":"3","author":"Blanco","year":"2013","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152505_bib0014","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1093\/annonc\/mdv252","article-title":"Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)","volume":"26","author":"Grande","year":"2015","journal-title":"Ann Oncol"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.672499","article-title":"Are markers of systemic inflammatory response useful in the management of patients with neuroendocrine neoplasms?","volume":"12","author":"Giannetta","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"28","key":"10.1016\/j.seminoncol.2026.152505_bib0016","doi-asserted-by":"crossref","first-page":"44735","DOI":"10.18632\/oncotarget.8203","article-title":"Molecular and clinical significance of fibroblast growth factor 2 (FGF2 \/bFGF) in malignancies of solid and hematological cancers for personalized therapies","volume":"7","author":"Akl","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0017","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.665631","article-title":"Role of FGF system in neuroendocrine neoplasms: potential therapeutic applications","volume":"12","author":"Vitale","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"20","key":"10.1016\/j.seminoncol.2026.152505_bib0018","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1200\/JCO.20.03368","article-title":"Lenvatinib in patients with advanced grade 1\/2 pancreatic and gastrointestinal neuroendocrine tumors: results of the phase II TALENT trial (GETNE1509)","volume":"39","author":"Capdevila","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152505_bib0019","doi-asserted-by":"crossref","DOI":"10.1530\/ERC-25-0052","article-title":"Impact of multikinase inhibitors in reshaping the treatment of advanced gastroenteropancreatic neuroendocrine tumors","volume":"32","author":"Siebenh\u00fcner","year":"2025","journal-title":"Endocr Relat Cancer"},{"issue":"24","key":"10.1016\/j.seminoncol.2026.152505_bib0020","doi-asserted-by":"crossref","first-page":"6114","DOI":"10.3390\/cancers14246114","article-title":"Mechanisms of resistance in gastroenteropancreatic neuroendocrine tumors","volume":"14","author":"Shi","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152505_bib0021","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1080\/14656566.2018.1476492","article-title":"Everolimus in the treatment of neuroendocrine tumors: efficacy, side-effects, resistance, and factors affecting its place in the treatment sequence","volume":"19","author":"Lee","year":"2018","journal-title":"Expert Opin Pharmacother"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0022","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.soc.2019.11.004","article-title":"Medical management of gastroenteropancreatic neuroendocrine tumors","volume":"29","author":"Chandrasekharan","year":"2020","journal-title":"Surg Oncol Clin N Am"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0023","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1215\/S1152851705000232","article-title":"The role of pericytes in blood-vessel formation and maintenance","volume":"7","author":"Bergers","year":"2005","journal-title":"Neuro Oncol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152505_bib0024","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152505_bib0025","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/nm884","article-title":"Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1","volume":"9","author":"Autiero","year":"2003","journal-title":"Nat Med"},{"issue":"24","key":"10.1016\/j.seminoncol.2026.152505_bib0026","doi-asserted-by":"crossref","first-page":"9739","DOI":"10.3390\/ijms21249739","article-title":"The roles of matrix metalloproteinases and their inhibitors in Human diseases","volume":"21","author":"Cabral-Pacheco","year":"2020","journal-title":"Int J Mol Sci"},{"issue":"22","key":"10.1016\/j.seminoncol.2026.152505_bib0027","doi-asserted-by":"crossref","first-page":"5730","DOI":"10.3390\/cancers13225730","article-title":"Targeting Tie2 in the tumor microenvironment: from angiogenesis to dissemination","volume":"13","author":"Duran","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152505_bib0028","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s40265-021-01605-y","article-title":"Targeting the angiopoietin\/tie pathway: prospects for treatment of retinal and respiratory disorders","volume":"81","author":"Akwii","year":"2021","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0029","doi-asserted-by":"crossref","first-page":"336","DOI":"10.7150\/thno.7851","article-title":"PI3K-AKT-mTOR-signaling and beyond: the complex network in gastroenteropancreatic neuroendocrine neoplasms","volume":"4","author":"Briest","year":"2014","journal-title":"Theranostics"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152505_bib0030","doi-asserted-by":"crossref","first-page":"R551","DOI":"10.1530\/ERC-16-0151","article-title":"Somatostatin analogues in acromegaly and gastroenteropancreatic neuroendocrine tumours: past, present and future","volume":"23","author":"\u00d6berg","year":"2016","journal-title":"Endocr Relat Cancer"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152505_bib0031","doi-asserted-by":"crossref","first-page":"3049","DOI":"10.3390\/ijms20123049","article-title":"Somatostatin analogues in the treatment of neuroendocrine tumors: past, present and future","volume":"20","author":"Stueven","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152505_bib0032","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.tem.2013.11.003","article-title":"Somatostatin analogs: does pharmacology impact antitumor efficacy?","volume":"25","author":"Chalabi","year":"2014","journal-title":"Trends Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152505_bib0033","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s00109-008-0337-z","article-title":"R regulation of tumor angiogenesis and metastasis by FGF and PDGF signaling pathways","volume":"86","author":"Cao","year":"2008","journal-title":"J Mol Med (Berl)"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152505_bib0034","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1172\/JCI28984","article-title":"PDGFRs are critical for PI3K\/akt activation and negatively regulated by mTOR","volume":"117","author":"Zhang","year":"2007","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0035","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000334891","article-title":"EGFR\/tgf\u03b1 and tgf\u03b2\/CTGF signaling in neuroendocrine neoplasia: theoretical therapeutic targets","volume":"97","author":"Kidd","year":"2013","journal-title":"Neuroendocrinology"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0036","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1152\/physrev.00046.2011","article-title":"Stem cell factor receptor\/c-kit: from basic science to clinical implications","volume":"92","author":"Lennartsson","year":"2012","journal-title":"Physiol Rev"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0037","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/s41392-025-02325-5","article-title":"Dual roles and therapeutic targeting of tumor-associated macrophages in tumor microenvironments","volume":"10","author":"Xu","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152505_bib0038","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"issue":"7643","key":"10.1016\/j.seminoncol.2026.152505_bib0039","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/nature21063","article-title":"Whole-genome landscape of pancreatic neuroendocrine tumours","volume":"543","author":"Scarpa","year":"2017","journal-title":"Nature"},{"issue":"Si-2","key":"10.1016\/j.seminoncol.2026.152505_bib0040","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.3906\/sag-2002-133","article-title":"Tuberous sclerosis: a review of the past, present, and future","volume":"50","author":"Uysal","year":"2020","journal-title":"Turk J Med Sci"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0041","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1186\/s13023-021-01929-8","article-title":"A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations","volume":"16","author":"Canaud","year":"2021","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0042","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40246-017-0109-3","article-title":"The NF1 somatic mutational landscape in sporadic human cancers","volume":"11","author":"Philpott","year":"2017","journal-title":"Hum Genomics"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152505_bib0043","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1016\/S1474-4422(14)70063-8","article-title":"Neurofibromatosis type 1: a multidisciplinary approach to care","volume":"13","author":"Hirbe","year":"2014","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0044","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/B978-0-444-62702-5.00010-X","article-title":"Von Hippel-Lindau disease","volume":"132","author":"Chittiboina","year":"2015","journal-title":"Handb Clin Neurol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1080\/19336918.2021.1909899","article-title":"Nicotinate-curcumin inhibits AngII-induced vascular smooth muscle cell phenotype switching by upregulating Daxx expression","volume":"15","author":"Sun","year":"2021","journal-title":"Cell Adh Migr"},{"issue":"13","key":"10.1016\/j.seminoncol.2026.152505_bib0046","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1158\/0008-5472.CAN-22-3599","article-title":"MEN1 Degradation induced by neddylation and the CUL4B-DCAF7 axis promotes pancreatic neuroendocrine tumor progression","volume":"83","author":"Xu","year":"2023","journal-title":"Cancer Res"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0047","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3389\/fendo.2018.00338","article-title":"PTEN: tumor suppressor and metabolic regulator","volume":"9","author":"Chen","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152505_bib0048","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1111\/epi.16370","article-title":"GATORopathies: the role of amino acid regulatory gene mutations in epilepsy and cortical malformations","volume":"60","author":"Iffland","year":"2019","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0049","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1210\/endrev\/bnac025","article-title":"Hypoxia-inducible factor 2 alpha (HIF2\u03b1) inhibitors: targeting genetically driven tumor Hypoxia","volume":"44","author":"Toledo","year":"2023","journal-title":"Endocr Rev"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152505_bib0050","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.10.023","article-title":"An organoid biobank of neuroendocrine neoplasms enables genotype-phenotype mapping","volume":"183","author":"Kawasaki","year":"2020","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0051","doi-asserted-by":"crossref","first-page":"R37","DOI":"10.1530\/JME-12-0069","article-title":"Molecular pathology and genetics of pancreatic endocrine tumours","volume":"49","author":"Capurso","year":"2012","journal-title":"J Mol Endocrinol"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152505_bib0052","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.3390\/cancers11081197","article-title":"Targeting oncogenic BRAF: past, present, and future","volume":"11","author":"Zaman","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0053","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.canlet.2010.02.018","article-title":"Compensatory activation of Akt in response to mTOR and Raf inhibitors - a rationale for dual-targeted therapy approaches in neuroendocrine tumor disease","volume":"295","author":"Zitzmann","year":"2010","journal-title":"Cancer Lett"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0054","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1172\/JCI73939","article-title":"mTOR: a pharmacologic target for autophagy regulation","volume":"125","author":"Kim","year":"2015","journal-title":"J Clin Invest"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0055","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152505_bib0056","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152505_bib0057","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1091\/mbc.02-02-0017","article-title":"Hypoxia-inducible factor-1alpha mRNA contains an internal ribosome entry site that allows efficient translation during normoxia and hypoxia","volume":"13","author":"Lang","year":"2002","journal-title":"Mol Biol Cell"},{"issue":"20","key":"10.1016\/j.seminoncol.2026.152505_bib0058","doi-asserted-by":"crossref","first-page":"6593","DOI":"10.1093\/nar\/gki958","article-title":"A second look at cellular mRNA sequences said to function as internal ribosome entry sites","volume":"33","author":"Kozak","year":"2005","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152505_bib0059","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/17460441.2019.1613370","article-title":"The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy","volume":"14","author":"Albadari","year":"2019","journal-title":"Expert Opin Drug Discov"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0060","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/549412","article-title":"Hypoxia-inducible factor-1 in physiological and pathophysiological angiogenesis: applications and therapies","volume":"2015","author":"Zimna","year":"2015","journal-title":"Biomed Res Int"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0061","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1182\/blood-2004-07-2958","article-title":"Transcriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1","volume":"105","author":"Manalo","year":"2005","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0062","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.cell.2017.06.009","article-title":"RAS proteins and their regulators in Human disease","volume":"170","author":"Simanshu","year":"2017","journal-title":"Cell"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0063","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.ccell.2020.03.013","article-title":"Targeting the MAPK pathway in KRAS-driven tumors","volume":"37","author":"Drosten","year":"2020","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152505_bib0064","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1677\/ERC-07-0288","article-title":"Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms","volume":"15","author":"Grozinsky-Glasberg","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0065","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.2147\/OTT.S127803","article-title":"Pancreatic neuroendocrine neoplasms at magnetic resonance imaging: comparison between grade 3 and grade 1\/2 tumors","volume":"10","author":"Guo","year":"2017","journal-title":"Onco Targets Ther"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152505_bib0066","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1158\/1535-7163.MCT-17-0241","article-title":"The selective Tie2 inhibitor rebastinib blocks recruitment and function of Tie2(Hi) macrophages in breast cancer and pancreatic neuroendocrine tumors","volume":"16","author":"Harney","year":"2017","journal-title":"Mol Cancer Ther"},{"issue":"3-4","key":"10.1016\/j.seminoncol.2026.152505_bib0067","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s10555-007-9077-8","article-title":"Role of mTOR in solid tumor systems: a therapeutical target against primary tumor growth, metastases, and angiogenesis","volume":"26","author":"Seeliger","year":"2007","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0068","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.humpath.2013.09.024","article-title":"Angiogenesis and vascular maturation in neuroendocrine tumors","volume":"45","author":"Yazdani","year":"2014","journal-title":"Hum Pathol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152505_bib0069","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s10555-023-10121-2","article-title":"Potent molecular-targeted therapies for gastro-entero-pancreatic neuroendocrine carcinoma","volume":"42","author":"Ooki","year":"2023","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0070","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1530\/ERC-21-0152","article-title":"The molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms","volume":"29","author":"Venizelos","year":"2021","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0071","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000497355","article-title":"The tumor microenvironment in neuroendocrine tumors: biology and therapeutic implications","volume":"109","author":"Cives","year":"2019","journal-title":"Neuroendocrinology"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152505_bib0072","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.neo.2015.04.004","article-title":"Hematopoietic stem cell-derived cancer-associated fibroblasts are novel contributors to the pro-tumorigenic microenvironment","volume":"17","author":"McDonald","year":"2015","journal-title":"Neoplasia"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152505_bib0073","doi-asserted-by":"crossref","first-page":"3852","DOI":"10.1016\/j.cell.2021.06.024","article-title":"Fibroblasts: origins, definitions, and functions in health and disease","volume":"184","author":"Plikus","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0074","doi-asserted-by":"crossref","DOI":"10.1016\/j.smim.2020.101417","article-title":"Fibroblast heterogeneity in tumor micro-environment: role in immunosuppression and new therapies","volume":"48","author":"Mhaidly","year":"2020","journal-title":"Semin Immunol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0075","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1078-0432.CCR-06-1408","article-title":"Prognostic value of tumor architecture, tumor-associated vascular characteristics, and expression of angiogenic molecules in pancreatic endocrine tumors","volume":"13","author":"Takahashi","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0076","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41392-022-01080-1","article-title":"Hypoxia signaling in human health and diseases: implications and prospects for therapeutics","volume":"7","author":"Luo","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0077","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1102\/1470-7330.2012.0026","article-title":"Nuclear medicine imaging of gastro-entero-pancreatic neuroendocrine tumors. The key role of cellular differentiation and tumor grade: from theory to clinical practice","volume":"12","author":"Rust","year":"2012","journal-title":"Cancer Imaging"},{"issue":"A(1a)","key":"10.1016\/j.seminoncol.2026.152505_bib0078","doi-asserted-by":"crossref","first-page":"S83","DOI":"10.1102\/1470-7330.2010.9007","article-title":"Use of molecular targeted agents for the diagnosis, staging and therapy of neuroendocrine malignancy","volume":"10","author":"Hicks","year":"2010","journal-title":"Cancer Imaging"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0079","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1007\/s40618-021-01715-0","article-title":"Risk factors for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a three-centric case-control study","volume":"45","author":"Feola","year":"2022","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s11154-024-09937-2","article-title":"Nutritional status and gastroenteropancreatic neuroendocrine neoplasms: lights and shadows with a clinical guide from the NIKE Group","volume":"26","author":"Vitale","year":"2025","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0081","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1186\/s12967-024-04870-z","article-title":"Hypoxia upregulating ACSS2 enhances lipid metabolism reprogramming through HMGCS1 mediated PI3K\/AKT\/mTOR pathway to promote the progression of pancreatic neuroendocrine neoplasms","volume":"22","author":"Gu","year":"2024","journal-title":"J Transl Med"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152505_bib0082","doi-asserted-by":"crossref","first-page":"3201","DOI":"10.7150\/ijbs.96831","article-title":"Hypoxic tumor-derived exosomal miR-4488 induces macrophage M2 polarization to promote liver metastasis of pancreatic neuroendocrine neoplasm through RTN3\/FABP5 mediated fatty acid oxidation","volume":"20","author":"Lu","year":"2024","journal-title":"Int J Biol Sci"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152505_bib0083","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1002\/cac2.12183","article-title":"Improving antitumor immunity using antiangiogenic agents: mechanistic insights, current progress, and clinical challenges","volume":"41","author":"Li","year":"2021","journal-title":"Cancer Commun (Lond)"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0084","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31383-9","article-title":"Profiling the tumour immune microenvironment in pancreatic neuroendocrine neoplasms with multispectral imaging indicates distinct subpopulation characteristics concordant with WHO 2017 classification","volume":"8","author":"Takahashi","year":"2018","journal-title":"Sci Rep"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152505_bib0085","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1007\/s00262-020-02556-1","article-title":"Neuroendocrine tumours and their microenvironment","volume":"69","author":"de Hosson","year":"2020","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0086","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/cjp2.135","article-title":"Microenvironment and tumor inflammatory features improve prognostic prediction in gastro-entero-pancreatic neuroendocrine neoplasms","volume":"5","author":"Milione","year":"2019","journal-title":"J Pathol Clin Res"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152505_bib0087","doi-asserted-by":"crossref","first-page":"839","DOI":"10.6004\/jnccn.2021.0032","article-title":"Neuroendocrine and adrenal tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology","volume":"19","author":"Shah","year":"2021","journal-title":"J Natl Compr Canc Netw"},{"issue":"32","key":"10.1016\/j.seminoncol.2026.152505_bib0088","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.1200\/JCO.23.01529","article-title":"Systemic therapy for tumor control in metastatic well-differentiated gastroenteropancreatic neuroendocrine tumors: ASCO guideline","volume":"41","author":"Del Rivero","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0089","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4137\/CMO.S7350","article-title":"Safety and efficacy of sunitinib in patients with unresectable pancreatic neuroendocrine tumors","volume":"6","author":"Wiedmann","year":"2012","journal-title":"Clin Med Insights Oncol"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152505_bib0090","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of Cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152505_bib0091","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1016\/S1470-2045(20)30493-9","article-title":"Surufatinib in advanced pancreatic neuroendocrine tumours (SANET-p): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0092","doi-asserted-by":"crossref","first-page":"455","DOI":"10.3390\/biomedicines13020455","article-title":"Everolimus in the treatment of neuroendocrine tumors: lights and shadows","volume":"13","author":"Medici","year":"2025","journal-title":"Biomedicines"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0093","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241286751","article-title":"Tyrosine kinase inhibitors in patients with neuroendocrine neoplasms: a systematic literature review","volume":"16","author":"Taboada","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152505_bib0094","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1158\/2159-8290.CD-11-0151","article-title":"A shining light in the darkness for the treatment of pancreatic neuroendocrine tumors","volume":"1","author":"Capdevila","year":"2011","journal-title":"Cancer Discov"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s11523-012-0217-x","article-title":"Relevance of angiogenesis in neuroendocrine tumors","volume":"7","author":"Teul\u00e9","year":"2012","journal-title":"Target Oncol"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152505_bib0096","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1200\/JCO.2007.13.6374","article-title":"Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.seminoncol.2026.152505_bib0097","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1200\/JCO.2016.70.4072","article-title":"Phase III prospective randomized comparison trial of Depot Octreotide Plus Interferon Alfa-2b versus Depot Octreotide Plus Bevacizumab in patients with advanced carcinoid tumors: SWOG S0518","volume":"35","author":"Yao","year":"2017","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0098","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1093\/annonc\/mdw561","article-title":"Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study","volume":"28","author":"Faivre","year":"2017","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0099","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/jjco\/hyz009","article-title":"Efficacy and safety of sunitinib in Japanese patients with progressive, advanced\/metastatic, well-differentiated, unresectable pancreatic neuroendocrine tumors: final analyses from a phase II study","volume":"49","author":"Ito","year":"2019","journal-title":"Jpn J Clin Oncol"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152505_bib0100","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/bjc.2015.73","article-title":"Circulating cytokines and monocyte subpopulations as biomarkers of outcome and biological activity in sunitinib-treated patients with advanced neuroendocrine tumours","volume":"112","author":"Zurita","year":"2015","journal-title":"Br J Cancer"},{"issue":"17","key":"10.1016\/j.seminoncol.2026.152505_bib0101","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2217\/fon-2018-0934","article-title":"Pharmacogenomic analyses of sunitinib in patients with pancreatic neuroendocrine tumors","volume":"15","author":"Fazio","year":"2019","journal-title":"Future Oncol"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0102","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1159\/000487237","article-title":"Clinical and biomarker evaluations of Sunitinib in patients with grade 3 digestive neuroendocrine neoplasms","volume":"107","author":"Pellat","year":"2018","journal-title":"Neuroendocrinology"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152505_bib0103","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1016\/S1470-2045(20)30496-4","article-title":"Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study","volume":"21","author":"Xu","year":"2020","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152505_bib0104","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1038\/bjc.2013.470","article-title":"Phase II study of pazopanib monotherapy in metastatic gastroenteropancreatic neuroendocrine tumours","volume":"109","author":"Ahn","year":"2013","journal-title":"Br J Cancer"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152505_bib0105","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3390\/cancers12051201","article-title":"mTOR pathway expression as potential predictive biomarker in patients with advanced neuroendocrine tumors treated with Everolimus","volume":"12","author":"Gelsomino","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"10022","key":"10.1016\/j.seminoncol.2026.152505_bib0106","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","volume":"387","author":"Yao","year":"2016","journal-title":"Lancet"},{"issue":"18","key":"10.1016\/j.seminoncol.2026.152505_bib0107","doi-asserted-by":"crossref","first-page":"4471","DOI":"10.3390\/cancers14184471","volume":"14","author":"Cella","year":"2022","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102560","article-title":"Targeting neuroendocrine tumors with octreotide and lanreotide: key points for clinical practice from NET specialists","volume":"117","author":"La Salvia","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152505_bib0109","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0110","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s12020-013-0130-9","article-title":"Transarterial embolization (TAE) is equally effective and slightly safer than transarterial chemoembolization (TACE) to manage liver metastases in neuroendocrine tumors","volume":"47","author":"Fiore","year":"2014","journal-title":"Endocrine"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152505_bib0111","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9072302","article-title":"The role of interventional radiology for the treatment of hepatic metastases from neuroendocrine tumor: an updated review","volume":"9","author":"Barat","year":"2020","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0112","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/ajco.12438","article-title":"Hepatic artery embolization in advanced neuroendocrine tumors: efficacy and long-term outcomes","volume":"12","author":"Pericleous","year":"2016","journal-title":"Asia Pac J Clin Oncol"},{"issue":"6","key":"10.1016\/j.seminoncol.2026.152505_bib0113","doi-asserted-by":"crossref","first-page":"e537","DOI":"10.3747\/co.27.6205","article-title":"Comparison of transarterial bland and chemoembolization for neuroendocrine tumours: a systematic review and meta-analysis","volume":"27","author":"Tai","year":"2020","journal-title":"Curr Oncol"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0114","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s11912-021-01030-0","article-title":"Liver-directed therapies for neuroendocrine neoplasms","volume":"23","author":"Clift","year":"2021","journal-title":"Curr Oncol Rep"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0115","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1080\/14737140.2022.2039123","article-title":"Lenvatinib dose, efficacy, and safety in the treatment of multiple malignancies","volume":"22","author":"Motzer","year":"2022","journal-title":"Expert Rev Anticancer Ther"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152505_bib0116","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/sj.bjc.6603419","article-title":"A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas","volume":"95","author":"Duran","year":"2006","journal-title":"Br J Cancer"},{"issue":"10","key":"10.1016\/j.seminoncol.2026.152505_bib0117","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1080\/14740338.2017.1354984","article-title":"The safety of available treatments options for neuroendocrine tumors","volume":"16","author":"Faggiano","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0118","series-title":"Management of Neuroendocrine Tumors of the Pancreas and Digestive Tract: From Surgery to Targeted Therapies: A Multidisciplinary Approach","first-page":"141","article-title":"Clinical management of targeted therapies in neuroendocrine tumours","author":"Carter","year":"2014"},{"issue":"11-12Suppl7","key":"10.1016\/j.seminoncol.2026.152505_bib0119","doi-asserted-by":"crossref","first-page":"S245","DOI":"10.5489\/cuaj.4315","article-title":"Sunitinib side effects as surrogate biomarkers of efficacy","volume":"10","author":"Kollmannsberger","year":"2016","journal-title":"Can Urol Assoc J"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152505_bib0120","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1158\/1535-7163.MCT-10-1124","article-title":"New insights into molecular mechanisms of sunitinib-associated side effects","volume":"10","author":"Aparicio-Gallego","year":"2011","journal-title":"Mol Cancer Ther"},{"issue":"9","key":"10.1016\/j.seminoncol.2026.152505_bib0121","doi-asserted-by":"crossref","first-page":"765","DOI":"10.4161\/cbt.12.9.18138","article-title":"Sunitinib-induced asthenia: from molecular basis to clinical relief","volume":"12","author":"Aparicio","year":"2011","journal-title":"Cancer Biol Ther"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152505_bib0122","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1634\/theoncologist.2015-0420","article-title":"Efficacy and safety of Everolimus in extrapancreatic neuroendocrine tumor: a comprehensive review of literature","volume":"21","author":"Faggiano","year":"2016","journal-title":"Oncologist"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0123","doi-asserted-by":"crossref","first-page":"33","DOI":"10.3747\/co.22.2393","article-title":"Novel agents and associated toxicities of inhibitors of the pi3k\/Akt\/mtor pathway for the treatment of breast cancer","volume":"22","author":"Chia","year":"2015","journal-title":"Curr Oncol"},{"issue":"16","key":"10.1016\/j.seminoncol.2026.152505_bib0124","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1080\/14656566.2017.1391217","article-title":"Somatostatin analogs in the treatment of neuroendocrine tumors: current and emerging aspects","volume":"18","author":"Mazziotti","year":"2017","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.seminoncol.2026.152505_bib0125","series-title":"Encyclopedia of Endocrine Diseases.","first-page":"288","article-title":"Somatostatin analogs","author":"Boerlin","year":"2004"},{"issue":"8","key":"10.1016\/j.seminoncol.2026.152505_bib0126","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/nrc2442","article-title":"Modes of resistance to anti-angiogenic therapy","volume":"8","author":"Bergers","year":"2008","journal-title":"Nat Rev Cancer"},{"issue":"7","key":"10.1016\/j.seminoncol.2026.152505_bib0127","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.3390\/ijms22073765","article-title":"Anti-angiogenic therapy: current challenges and future perspectives","volume":"22","author":"Lopes-Coelho","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.seminoncol.2026.152505_bib0128","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/j.tranon.2017.04.007","article-title":"Vascular mimicry: a novel neovascularization mechanism driving anti-angiogenic therapy (AAT) resistance in glioblastoma","volume":"10","author":"Angara","year":"2017","journal-title":"Transl Oncol"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152505_bib0129","doi-asserted-by":"crossref","first-page":"R109","DOI":"10.1530\/ERC-18-0420","article-title":"Resistance to targeted treatment of gastroenteropancreatic neuroendocrine tumors","volume":"26","author":"Beyens","year":"2019","journal-title":"Endocr Relat Cancer"},{"issue":"3","key":"10.1016\/j.seminoncol.2026.152505_bib0130","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s11523-012-0226-9","article-title":"Profiling mTOR pathway in neuroendocrine tumors","volume":"7","author":"Cingarlini","year":"2012","journal-title":"Target Oncol"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0131","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in Acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.seminoncol.2026.152505_bib0132","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2023.101794","article-title":"Precision medicine in gastroenteropancreatic neuroendocrine neoplasms: where are we in 2023?","volume":"37","author":"Fazio","year":"2023","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"18","key":"10.1016\/j.seminoncol.2026.152505_bib0133","doi-asserted-by":"crossref","first-page":"2877","DOI":"10.3390\/diagnostics13182877","article-title":"Prognostic assessment of gastropancreatic neuroendocrine neoplasm: prospects and limits of radiomics","volume":"13","author":"De Muzio","year":"2023","journal-title":"Diagnostics (Basel)"},{"issue":"2","key":"10.1016\/j.seminoncol.2026.152505_bib0134","first-page":"158","article-title":"Recent advances and future challenges in the diagnosis of neuroendocrine neoplasms","volume":"49","author":"Modica","year":"2024","journal-title":"Minerva Endocrinol (Torino)"},{"issue":"1","key":"10.1016\/j.seminoncol.2026.152505_bib0135","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1007\/s00330-021-08146-8","article-title":"Radiomic machine learning for predicting prognostic biomarkers and molecular subtypes of breast cancer using tumor heterogeneity and angiogenesis properties on MRI","volume":"32","author":"Lee","year":"2022","journal-title":"Eur Radiol"},{"issue":"11","key":"10.1016\/j.seminoncol.2026.152505_bib0136","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00261-023-04007-8","article-title":"DCE-MRI-based radiomics in predicting angiopoietin-2 expression in hepatocellular carcinoma","volume":"48","author":"Zheng","year":"2023","journal-title":"Abdom Radiol (NY)"},{"issue":"12","key":"10.1016\/j.seminoncol.2026.152505_bib0137","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1093\/neuonc\/nox092","article-title":"Quantitative imaging biomarkers for risk stratification of patients with recurrent glioblastoma treated with bevacizumab","volume":"19","author":"Grossmann","year":"2017","journal-title":"Neuro Oncol"}],"container-title":["Seminars in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000527?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0093775426000527?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T12:48:03Z","timestamp":1788612483000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0093775426000527"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":137,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0093775426000527"],"URL":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152505","relation":{},"ISSN":["0093-7754"],"issn-type":[{"value":"0093-7754","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiogenesis and the corresponding antiangiogenic therapy in gastroenteropancreatic neuroendocrine neoplasms","name":"articletitle","label":"Article Title"},{"value":"Seminars in Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seminoncol.2026.152505","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"152505"}}